Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation

Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammatory bowel diseases 2020-01, Vol.26 (2), p.216-228
Hauptverfasser: Karuppuchamy, Thangaraj, Tyler, Christopher J, Lundborg, Luke R, Pérez-Jeldres, Tamara, Kimball, Abigail K, Clambey, Eric T, Jedlicka, Paul, Rivera-Nieves, Jesús
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 228
container_issue 2
container_start_page 216
container_title Inflammatory bowel diseases
container_volume 26
creator Karuppuchamy, Thangaraj
Tyler, Christopher J
Lundborg, Luke R
Pérez-Jeldres, Tamara
Kimball, Abigail K
Clambey, Eric T
Jedlicka, Paul
Rivera-Nieves, Jesús
description Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymocyte maturation. Abstract Background Lymphocytes recirculate from tissues to blood following the sphingosine-1-phosphate (S1P) gradient (low in tissues, high in blood), maintained by synthetic and degradative enzymes, among which the S1P lyase (SPL) irreversibly degrades S1P. The role of SPL in the intestine, both during homeostasis and IBD, is poorly understood. We hypothesized that modulation of tissue S1P levels might be advantageous over S1P receptor (S1PR) agonists (eg, fingolimod, ozanimod, etrasimod), as without S1PR engagement there might be less likelihood of potential off-target effects. Methods First we examined SPL mRNA transcripts and SPL localization in tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The in vivo effects of the SPL inhibitors 4-deoxypyridoxine hydrochloride (30 mg/L) and 2-acetyl-4 (tetrahydroxybutyl)imidazole (50 mg/L) were assessed through their oral administration to adult TNF∆ARE mice, which spontaneously develop Crohn’s-like chronic ileitis. The effect of SPL inhibition on circulating and tissue lymphocytes, transcriptional regulation of proinflammatory cytokines, and on the histological severity of ileitis was additionally examined. Tissue S1P levels were determined by liquid chromatography–mass spectrometry. Mechanistically, the potential effects of high S1P tissue levels on intestinal leukocyte apoptosis were assessed via terminal deoxynucleotidyl transferase dUTP nick end-labeling assay and annexin 5 staining. Finally, we examined the ability of T cells to home to the intestine, along with the effects of SPL inhibition on cellular subsets within immune compartments via flow and mass cytometry. Results S1P lyase was ubiquitously expressed. In the gut, immunohistochemistry predominantly localized it to small intestinal epithelia, although the lamina propria leukocyte fraction had higher mRNA transcripts. Inhibition of SPL markedly increased local intestinal S1P levels, induced peripheral lymphopenia, downregulated proinflammatory cytokines, and attenuated chronic ileitis in mice. SPL inhibition reduced T and myeloid cells in secondary lymphoid tissues and the intestine and dec
doi_str_mv 10.1093/ibd/izz174
format Article
fullrecord <record><control><sourceid>gale_oup_p</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6943703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A618129210</galeid><oup_id>10.1093/ibd/izz174</oup_id><sourcerecordid>A618129210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-526af7801b5e22bcda39d669f10a57fb678ab2ef2e7e79666222a4ecb06ccb073</originalsourceid><addsrcrecordid>eNqNkt-K1DAUxoso7h-98QEkIMKidDdJ26S9EYZB14URF2a9Dml6Oo22Sbdpldkr730CX88n8YxdBxdE5EASkt_3nRzOiaInjJ4yWiRntqzO7M0Nk-m96JBliYjTPE3v45nKPKZFkR9ERyF8pJRjFA-jg4TlVMqMHUbf1n1j3cYH6yBm8WXjQ9_oEchqqwOQC9fY0o7WO7JoRxgCGRsga3ZJzgddWXAj0a4iiw5a6wfUBbIcfON-fP0e4pX9hA4toD6QckvWU98PEDDVhlw1286bLSZ6p8cJlZjiUfSg1m2Ax7f7cfThzeur5dt49f78YrlYxSaV2RhnXOha5pSVGXBemkonRSVEUTOqM1mXQua65FBzkCALIQTnXKdgSioMLjI5jl7Nvv1UdlAZrGLQreoH2-lhq7y26u6Ls43a-M9KFGkiaYIGJ7cGg7-eIIyqs8FA22oHfgqKJ5zLNMXEiD6b0Y1uQVlXe3Q0O1wtBMsZLzijSJ3-hcKooLPGO6gt3t8RvJgFZvAhDFDvf8-o2g2FwqFQ81Ag_PTPevfo7ylA4OUMfIHS18FgXw3sMUppRgWiCZ7Yrvr8_-mlHX_1duknN6L0-Sz1U_-vH_8E4LXjqw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322744622</pqid></control><display><type>article</type><title>Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Karuppuchamy, Thangaraj ; Tyler, Christopher J ; Lundborg, Luke R ; Pérez-Jeldres, Tamara ; Kimball, Abigail K ; Clambey, Eric T ; Jedlicka, Paul ; Rivera-Nieves, Jesús</creator><creatorcontrib>Karuppuchamy, Thangaraj ; Tyler, Christopher J ; Lundborg, Luke R ; Pérez-Jeldres, Tamara ; Kimball, Abigail K ; Clambey, Eric T ; Jedlicka, Paul ; Rivera-Nieves, Jesús</creatorcontrib><description>Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymocyte maturation. Abstract Background Lymphocytes recirculate from tissues to blood following the sphingosine-1-phosphate (S1P) gradient (low in tissues, high in blood), maintained by synthetic and degradative enzymes, among which the S1P lyase (SPL) irreversibly degrades S1P. The role of SPL in the intestine, both during homeostasis and IBD, is poorly understood. We hypothesized that modulation of tissue S1P levels might be advantageous over S1P receptor (S1PR) agonists (eg, fingolimod, ozanimod, etrasimod), as without S1PR engagement there might be less likelihood of potential off-target effects. Methods First we examined SPL mRNA transcripts and SPL localization in tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The in vivo effects of the SPL inhibitors 4-deoxypyridoxine hydrochloride (30 mg/L) and 2-acetyl-4 (tetrahydroxybutyl)imidazole (50 mg/L) were assessed through their oral administration to adult TNF∆ARE mice, which spontaneously develop Crohn’s-like chronic ileitis. The effect of SPL inhibition on circulating and tissue lymphocytes, transcriptional regulation of proinflammatory cytokines, and on the histological severity of ileitis was additionally examined. Tissue S1P levels were determined by liquid chromatography–mass spectrometry. Mechanistically, the potential effects of high S1P tissue levels on intestinal leukocyte apoptosis were assessed via terminal deoxynucleotidyl transferase dUTP nick end-labeling assay and annexin 5 staining. Finally, we examined the ability of T cells to home to the intestine, along with the effects of SPL inhibition on cellular subsets within immune compartments via flow and mass cytometry. Results S1P lyase was ubiquitously expressed. In the gut, immunohistochemistry predominantly localized it to small intestinal epithelia, although the lamina propria leukocyte fraction had higher mRNA transcripts. Inhibition of SPL markedly increased local intestinal S1P levels, induced peripheral lymphopenia, downregulated proinflammatory cytokines, and attenuated chronic ileitis in mice. SPL inhibition reduced T and myeloid cells in secondary lymphoid tissues and the intestine and decreased naïve T-cell recruitment. The anti-inflammatory activity of SPL inhibition was not mediated by leukocyte apoptosis, nor by interference with the homing of lymphocytes to the intestine, and was independent of its peripheral lymphopenic effect. However, SPL inhibition promoted thymic atrophy and depleted late immature T cells (CD4+CD8+ double positive), with accumulation of mature CD4+CD8- and CD4-CD8+ single-positive cells. Conclusions Inhibition of the S1P lyase alters the S1P gradient and attenuates chronic ileitis via central immunosuppression. SPL inhibition could represent a potential way to tame an overactive immune response during IBD and other T-cell-mediated chronic inflammatory diseases.</description><identifier>ISSN: 1078-0998</identifier><identifier>EISSN: 1536-4844</identifier><identifier>DOI: 10.1093/ibd/izz174</identifier><identifier>PMID: 31807751</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Aldehyde-Lyases - antagonists &amp; inhibitors ; Animals ; Anti-Inflammatory Agents - pharmacology ; Basic Science Research ; Crohn Disease - drug therapy ; Crohn Disease - metabolism ; Crohn Disease - pathology ; Enzymes ; Ethylenediaminetetraacetic acid ; Fingolimod ; Gastroenterology &amp; Hepatology ; Ileitis - drug therapy ; Ileitis - metabolism ; Ileitis - pathology ; Immunohistochemistry ; Life Sciences &amp; Biomedicine ; Lysophospholipids - metabolism ; Mice ; Phosphates ; RNA ; Science &amp; Technology ; Sphingosine - analogs &amp; derivatives ; Sphingosine - metabolism ; T cells ; Thymocytes - drug effects ; Thymocytes - pathology ; Tumor Necrosis Factor-alpha - genetics ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Inflammatory bowel diseases, 2020-01, Vol.26 (2), p.216-228</ispartof><rights>2019 Crohn’s &amp; Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2019</rights><rights>2019 Crohn’s &amp; Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>COPYRIGHT 2020 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>22</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000506807300013</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c475t-526af7801b5e22bcda39d669f10a57fb678ab2ef2e7e79666222a4ecb06ccb073</citedby><cites>FETCH-LOGICAL-c475t-526af7801b5e22bcda39d669f10a57fb678ab2ef2e7e79666222a4ecb06ccb073</cites><orcidid>0000-0002-9831-386X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31807751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karuppuchamy, Thangaraj</creatorcontrib><creatorcontrib>Tyler, Christopher J</creatorcontrib><creatorcontrib>Lundborg, Luke R</creatorcontrib><creatorcontrib>Pérez-Jeldres, Tamara</creatorcontrib><creatorcontrib>Kimball, Abigail K</creatorcontrib><creatorcontrib>Clambey, Eric T</creatorcontrib><creatorcontrib>Jedlicka, Paul</creatorcontrib><creatorcontrib>Rivera-Nieves, Jesús</creatorcontrib><title>Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation</title><title>Inflammatory bowel diseases</title><addtitle>INFLAMM BOWEL DIS</addtitle><addtitle>Inflamm Bowel Dis</addtitle><description>Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymocyte maturation. Abstract Background Lymphocytes recirculate from tissues to blood following the sphingosine-1-phosphate (S1P) gradient (low in tissues, high in blood), maintained by synthetic and degradative enzymes, among which the S1P lyase (SPL) irreversibly degrades S1P. The role of SPL in the intestine, both during homeostasis and IBD, is poorly understood. We hypothesized that modulation of tissue S1P levels might be advantageous over S1P receptor (S1PR) agonists (eg, fingolimod, ozanimod, etrasimod), as without S1PR engagement there might be less likelihood of potential off-target effects. Methods First we examined SPL mRNA transcripts and SPL localization in tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The in vivo effects of the SPL inhibitors 4-deoxypyridoxine hydrochloride (30 mg/L) and 2-acetyl-4 (tetrahydroxybutyl)imidazole (50 mg/L) were assessed through their oral administration to adult TNF∆ARE mice, which spontaneously develop Crohn’s-like chronic ileitis. The effect of SPL inhibition on circulating and tissue lymphocytes, transcriptional regulation of proinflammatory cytokines, and on the histological severity of ileitis was additionally examined. Tissue S1P levels were determined by liquid chromatography–mass spectrometry. Mechanistically, the potential effects of high S1P tissue levels on intestinal leukocyte apoptosis were assessed via terminal deoxynucleotidyl transferase dUTP nick end-labeling assay and annexin 5 staining. Finally, we examined the ability of T cells to home to the intestine, along with the effects of SPL inhibition on cellular subsets within immune compartments via flow and mass cytometry. Results S1P lyase was ubiquitously expressed. In the gut, immunohistochemistry predominantly localized it to small intestinal epithelia, although the lamina propria leukocyte fraction had higher mRNA transcripts. Inhibition of SPL markedly increased local intestinal S1P levels, induced peripheral lymphopenia, downregulated proinflammatory cytokines, and attenuated chronic ileitis in mice. SPL inhibition reduced T and myeloid cells in secondary lymphoid tissues and the intestine and decreased naïve T-cell recruitment. The anti-inflammatory activity of SPL inhibition was not mediated by leukocyte apoptosis, nor by interference with the homing of lymphocytes to the intestine, and was independent of its peripheral lymphopenic effect. However, SPL inhibition promoted thymic atrophy and depleted late immature T cells (CD4+CD8+ double positive), with accumulation of mature CD4+CD8- and CD4-CD8+ single-positive cells. Conclusions Inhibition of the S1P lyase alters the S1P gradient and attenuates chronic ileitis via central immunosuppression. SPL inhibition could represent a potential way to tame an overactive immune response during IBD and other T-cell-mediated chronic inflammatory diseases.</description><subject>Aldehyde-Lyases - antagonists &amp; inhibitors</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Basic Science Research</subject><subject>Crohn Disease - drug therapy</subject><subject>Crohn Disease - metabolism</subject><subject>Crohn Disease - pathology</subject><subject>Enzymes</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>Fingolimod</subject><subject>Gastroenterology &amp; Hepatology</subject><subject>Ileitis - drug therapy</subject><subject>Ileitis - metabolism</subject><subject>Ileitis - pathology</subject><subject>Immunohistochemistry</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Lysophospholipids - metabolism</subject><subject>Mice</subject><subject>Phosphates</subject><subject>RNA</subject><subject>Science &amp; Technology</subject><subject>Sphingosine - analogs &amp; derivatives</subject><subject>Sphingosine - metabolism</subject><subject>T cells</subject><subject>Thymocytes - drug effects</subject><subject>Thymocytes - pathology</subject><subject>Tumor Necrosis Factor-alpha - genetics</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>1078-0998</issn><issn>1536-4844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkt-K1DAUxoso7h-98QEkIMKidDdJ26S9EYZB14URF2a9Dml6Oo22Sbdpldkr730CX88n8YxdBxdE5EASkt_3nRzOiaInjJ4yWiRntqzO7M0Nk-m96JBliYjTPE3v45nKPKZFkR9ERyF8pJRjFA-jg4TlVMqMHUbf1n1j3cYH6yBm8WXjQ9_oEchqqwOQC9fY0o7WO7JoRxgCGRsga3ZJzgddWXAj0a4iiw5a6wfUBbIcfON-fP0e4pX9hA4toD6QckvWU98PEDDVhlw1286bLSZ6p8cJlZjiUfSg1m2Ax7f7cfThzeur5dt49f78YrlYxSaV2RhnXOha5pSVGXBemkonRSVEUTOqM1mXQua65FBzkCALIQTnXKdgSioMLjI5jl7Nvv1UdlAZrGLQreoH2-lhq7y26u6Ls43a-M9KFGkiaYIGJ7cGg7-eIIyqs8FA22oHfgqKJ5zLNMXEiD6b0Y1uQVlXe3Q0O1wtBMsZLzijSJ3-hcKooLPGO6gt3t8RvJgFZvAhDFDvf8-o2g2FwqFQ81Ag_PTPevfo7ylA4OUMfIHS18FgXw3sMUppRgWiCZ7Yrvr8_-mlHX_1duknN6L0-Sz1U_-vH_8E4LXjqw</recordid><startdate>20200106</startdate><enddate>20200106</enddate><creator>Karuppuchamy, Thangaraj</creator><creator>Tyler, Christopher J</creator><creator>Lundborg, Luke R</creator><creator>Pérez-Jeldres, Tamara</creator><creator>Kimball, Abigail K</creator><creator>Clambey, Eric T</creator><creator>Jedlicka, Paul</creator><creator>Rivera-Nieves, Jesús</creator><general>Oxford University Press</general><general>Oxford Univ Press</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9831-386X</orcidid></search><sort><creationdate>20200106</creationdate><title>Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation</title><author>Karuppuchamy, Thangaraj ; Tyler, Christopher J ; Lundborg, Luke R ; Pérez-Jeldres, Tamara ; Kimball, Abigail K ; Clambey, Eric T ; Jedlicka, Paul ; Rivera-Nieves, Jesús</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-526af7801b5e22bcda39d669f10a57fb678ab2ef2e7e79666222a4ecb06ccb073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aldehyde-Lyases - antagonists &amp; inhibitors</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Basic Science Research</topic><topic>Crohn Disease - drug therapy</topic><topic>Crohn Disease - metabolism</topic><topic>Crohn Disease - pathology</topic><topic>Enzymes</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>Fingolimod</topic><topic>Gastroenterology &amp; Hepatology</topic><topic>Ileitis - drug therapy</topic><topic>Ileitis - metabolism</topic><topic>Ileitis - pathology</topic><topic>Immunohistochemistry</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Lysophospholipids - metabolism</topic><topic>Mice</topic><topic>Phosphates</topic><topic>RNA</topic><topic>Science &amp; Technology</topic><topic>Sphingosine - analogs &amp; derivatives</topic><topic>Sphingosine - metabolism</topic><topic>T cells</topic><topic>Thymocytes - drug effects</topic><topic>Thymocytes - pathology</topic><topic>Tumor Necrosis Factor-alpha - genetics</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karuppuchamy, Thangaraj</creatorcontrib><creatorcontrib>Tyler, Christopher J</creatorcontrib><creatorcontrib>Lundborg, Luke R</creatorcontrib><creatorcontrib>Pérez-Jeldres, Tamara</creatorcontrib><creatorcontrib>Kimball, Abigail K</creatorcontrib><creatorcontrib>Clambey, Eric T</creatorcontrib><creatorcontrib>Jedlicka, Paul</creatorcontrib><creatorcontrib>Rivera-Nieves, Jesús</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Inflammatory bowel diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karuppuchamy, Thangaraj</au><au>Tyler, Christopher J</au><au>Lundborg, Luke R</au><au>Pérez-Jeldres, Tamara</au><au>Kimball, Abigail K</au><au>Clambey, Eric T</au><au>Jedlicka, Paul</au><au>Rivera-Nieves, Jesús</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation</atitle><jtitle>Inflammatory bowel diseases</jtitle><stitle>INFLAMM BOWEL DIS</stitle><addtitle>Inflamm Bowel Dis</addtitle><date>2020-01-06</date><risdate>2020</risdate><volume>26</volume><issue>2</issue><spage>216</spage><epage>228</epage><pages>216-228</pages><issn>1078-0998</issn><eissn>1536-4844</eissn><abstract>Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymocyte maturation. Abstract Background Lymphocytes recirculate from tissues to blood following the sphingosine-1-phosphate (S1P) gradient (low in tissues, high in blood), maintained by synthetic and degradative enzymes, among which the S1P lyase (SPL) irreversibly degrades S1P. The role of SPL in the intestine, both during homeostasis and IBD, is poorly understood. We hypothesized that modulation of tissue S1P levels might be advantageous over S1P receptor (S1PR) agonists (eg, fingolimod, ozanimod, etrasimod), as without S1PR engagement there might be less likelihood of potential off-target effects. Methods First we examined SPL mRNA transcripts and SPL localization in tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The in vivo effects of the SPL inhibitors 4-deoxypyridoxine hydrochloride (30 mg/L) and 2-acetyl-4 (tetrahydroxybutyl)imidazole (50 mg/L) were assessed through their oral administration to adult TNF∆ARE mice, which spontaneously develop Crohn’s-like chronic ileitis. The effect of SPL inhibition on circulating and tissue lymphocytes, transcriptional regulation of proinflammatory cytokines, and on the histological severity of ileitis was additionally examined. Tissue S1P levels were determined by liquid chromatography–mass spectrometry. Mechanistically, the potential effects of high S1P tissue levels on intestinal leukocyte apoptosis were assessed via terminal deoxynucleotidyl transferase dUTP nick end-labeling assay and annexin 5 staining. Finally, we examined the ability of T cells to home to the intestine, along with the effects of SPL inhibition on cellular subsets within immune compartments via flow and mass cytometry. Results S1P lyase was ubiquitously expressed. In the gut, immunohistochemistry predominantly localized it to small intestinal epithelia, although the lamina propria leukocyte fraction had higher mRNA transcripts. Inhibition of SPL markedly increased local intestinal S1P levels, induced peripheral lymphopenia, downregulated proinflammatory cytokines, and attenuated chronic ileitis in mice. SPL inhibition reduced T and myeloid cells in secondary lymphoid tissues and the intestine and decreased naïve T-cell recruitment. The anti-inflammatory activity of SPL inhibition was not mediated by leukocyte apoptosis, nor by interference with the homing of lymphocytes to the intestine, and was independent of its peripheral lymphopenic effect. However, SPL inhibition promoted thymic atrophy and depleted late immature T cells (CD4+CD8+ double positive), with accumulation of mature CD4+CD8- and CD4-CD8+ single-positive cells. Conclusions Inhibition of the S1P lyase alters the S1P gradient and attenuates chronic ileitis via central immunosuppression. SPL inhibition could represent a potential way to tame an overactive immune response during IBD and other T-cell-mediated chronic inflammatory diseases.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>31807751</pmid><doi>10.1093/ibd/izz174</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-9831-386X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0998
ispartof Inflammatory bowel diseases, 2020-01, Vol.26 (2), p.216-228
issn 1078-0998
1536-4844
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6943703
source MEDLINE; Oxford University Press Journals All Titles (1996-Current)
subjects Aldehyde-Lyases - antagonists & inhibitors
Animals
Anti-Inflammatory Agents - pharmacology
Basic Science Research
Crohn Disease - drug therapy
Crohn Disease - metabolism
Crohn Disease - pathology
Enzymes
Ethylenediaminetetraacetic acid
Fingolimod
Gastroenterology & Hepatology
Ileitis - drug therapy
Ileitis - metabolism
Ileitis - pathology
Immunohistochemistry
Life Sciences & Biomedicine
Lysophospholipids - metabolism
Mice
Phosphates
RNA
Science & Technology
Sphingosine - analogs & derivatives
Sphingosine - metabolism
T cells
Thymocytes - drug effects
Thymocytes - pathology
Tumor Necrosis Factor-alpha - genetics
Tumor Necrosis Factor-alpha - metabolism
title Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A59%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_oup_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sphingosine-1-Phosphate%20Lyase%20Inhibition%20Alters%20the%20S1P%20Gradient%20and%20Ameliorates%20Crohn%E2%80%99s-Like%20Ileitis%20by%20Suppressing%20Thymocyte%20Maturation&rft.jtitle=Inflammatory%20bowel%20diseases&rft.au=Karuppuchamy,%20Thangaraj&rft.date=2020-01-06&rft.volume=26&rft.issue=2&rft.spage=216&rft.epage=228&rft.pages=216-228&rft.issn=1078-0998&rft.eissn=1536-4844&rft_id=info:doi/10.1093/ibd/izz174&rft_dat=%3Cgale_oup_p%3EA618129210%3C/gale_oup_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2322744622&rft_id=info:pmid/31807751&rft_galeid=A618129210&rft_oup_id=10.1093/ibd/izz174&rfr_iscdi=true